Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Preventive Healthcare Services01:30

Preventive Healthcare Services

Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do DMARDs increase the risk of cancer recurrence in patients with spondyloarthritis, psoriatic arthritis and rheumatoid arthritis?

Clinical and experimental rheumatology·2026
Same author

Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study.

Frontiers in immunology·2026
Same author

Switching from intravenous to subcutaneous infliximab in Behçet's disease: feasibility, safety and early outcomes.

Clinical and experimental rheumatology·2026
Same author

Advancing Care in Lupus Nephritis: Expert Perspectives on Current Practices and Future Directions in Italy.

Journal of clinical medicine·2026
Same author

Early belimumab accelerates renal response and reduces glucocorticoid exposure in lupus nephritis: a multicentre propensity-matched study.

Rheumatology (Oxford, England)·2026
Same author

Clinical and serological features of triple autoantibody-negative patients with systemic sclerosis: insights from the multicentric SPRING registry of the Italian Society for Rheumatology.

RMD open·2026

Related Experiment Video

Updated: Jul 8, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Preventive strategies in systemic lupus erythematosus.

Andrea Doria1, Silvia Arienti, Mariaelisa Rampudda

  • 1Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy. adoria@unipd.it

Autoimmunity Reviews
|January 15, 2008
PubMed
Summary

Improving long-term survival for systemic lupus erythematosus (SLE) requires early strategies to prevent complications like infections, atherosclerosis, and cancer. Proactive treatment for asymptomatic individuals with positive serology may also improve outcomes.

Related Experiment Videos

Last Updated: Jul 8, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Systemic lupus erythematosus (SLE) survival has improved, but long-term prognosis remains poor due to disease and treatment complications.
  • Autoantibodies in SLE often precede clinical symptoms, raising questions about early intervention in asymptomatic individuals.

Purpose of the Study:

  • To outline strategies for improving long-term prognosis in SLE patients.
  • To discuss the potential benefits of early intervention in asymptomatic individuals with positive serology.
  • To emphasize the need for identifying risk factors for severe SLE manifestations.

Main Methods:

  • Review of current understanding of SLE progression and complications.
  • Discussion of preventive strategies for infections, atherosclerosis, and cancer.
  • Consideration of early treatment options for asymptomatic individuals, including lifestyle modifications and pharmacotherapy.
  • Emphasis on identifying early risk factors for severe disease.

Main Results:

  • Early implementation of preventive strategies against infections, atherosclerosis, and cancer is crucial for improving SLE prognosis.
  • Lifestyle advice (sun avoidance, smoking cessation) and potential treatments (vitamin D, hydroxychloroquine) may benefit asymptomatic individuals with positive serology.
  • Early diagnosis has shifted the clinical spectrum towards milder initial manifestations, necessitating identification of factors predicting severe disease progression.

Conclusions:

  • Proactive management focusing on preventing long-term complications is essential for enhancing SLE patient outcomes.
  • Aggressive treatment may be warranted for mild SLE cases with identified risk factors for severe manifestations.
  • Further research is needed to identify predictive markers for severe SLE and optimize early intervention strategies.